At the J.P. Morgan Healthcare Conference in January, Regeneron CEO Leonard Schleifer said that the company’s new formulation of eye disease treatment Eylea needed “a few more arrows in its ...

QUASAR trial showed Eylea HD matched vision gains of standard Eylea with less frequent dosing. BofA cuts Regeneron price target to $547, maintains Underperform rating. Learn the top momentum ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron’s proposal to add additional ...

CEO Leonard Schleifer specifically cited a funding gap at patient assistance foundations as a catalyst for more patients and physicians turning to off-label Avastin over EYLEA, resulting in a ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

The FDA did not approve the supplemental biologics license application for Eylea HD. The application would have added extended dosing intervals greater than 16 weeks, if approved. Editor’s note ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review.

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Lead drug Eylea had global sales of just under $10 billion in 2024 and is approved for wet age-related macular degeneration and other eye-related indications. The majority of sales are for ...

A significant chunk of Regeneron’s revenues comes from the sale of its lead drug, Eylea, which is approved for various ophthalmology indications (neovascular age-related macular degeneration ...